Vivos Therapeutics appoints two executives to support growth strategy

LITTLETON, Colo. - Vivos Therapeutics, Inc. (NASDAQ:VVOS) announced Wednesday the appointment of Michael E. Bruhn as Executive Vice President of Business Operations Integration and Dr. Terry Jones as Senior Vice President of Human Resources. The company’s stock, which has shown a remarkable 105% return over the past year, currently trades near $4.46. According to InvestingPro analysis, the stock is trading close to its Fair Value, though investors should note its high volatility.

The appointments are aimed at strengthening the company’s ability to scale its sleep testing center and direct patient treatment operations, according to a press release. Both executives will report directly to Chairman and CEO R. Kirk Huntsman. The company faces operational challenges, with InvestingPro data showing significant cash burn and short-term obligations exceeding liquid assets, making these leadership appointments particularly crucial.

Bruhn will focus on expanding Vivos’ operations under its new business model, particularly in the Eastern United States, and managing the integration of acquisitions and collaborations. He previously served as Executive Vice President and Chief Operating Officer at the United States Institute of Peace, and has experience in federal healthcare consulting at IQVIA Holdings, Inc. Bruhn also served for over 20 years in the U.S. Air Force Medical Service.

Dr. Jones brings more than two decades of leadership experience across federal agencies, international nonprofits, and the private sector. Most recently, he served as Vice President of Human Resources at the United States Institute of Peace. Jones holds a Doctorate in Management, an MBA in Human Resources Management, and is a U.S. Air Force veteran.

Vivos Therapeutics develops and commercializes diagnostic and treatment methods for obstructive sleep apnea (OSA) and snoring. The company’s Complete Airway Repositioning and/or Expansion devices are FDA-cleared for adult patients with all severity levels of OSA and for moderate-to-severe OSA in children ages 6 to 17.

The company recently acquired The Sleep Center of Nevada and is exploring similar acquisitions or collaborations to scale revenue. Vivos noted that Bruhn and Susan McCullough, Executive Vice President of Operations and Co-Founder, are siblings. With current revenue of $14.6 million and a gross profit margin of 59%, investors awaiting the company’s next earnings report on August 13 can access comprehensive analysis through InvestingPro, which offers 12 additional key insights and detailed financial metrics for informed decision-making.

In other recent news, Vivos Therapeutics announced that its VidaSleep oral appliance has received approval from the Centers for Medicare & Medicaid Services (CMS) for treating mild to moderate obstructive sleep apnea and snoring in adults. This approval makes VidaSleep the second Vivos product to receive Medicare coverage, joining the company’s mmRNA device. Additionally, a multicenter clinical trial published in the European Journal of Pediatrics reported positive outcomes for Vivos’ Daytime-Nighttime Appliance in treating obstructive sleep apnea in children, with significant improvements noted in 79% of patients.

In a strategic move, Vivos has completed the acquisition of The Sleep Center of Nevada, the largest operator of medical sleep centers in the state, for $6 million in cash and $1.5 million in company stock. This acquisition marks Vivos’ shift from focusing on dental providers to collaborating with or acquiring medical sleep practices. Furthermore, Vivos Therapeutics has appointed Baker Tilly as its new independent registered public accounting firm following a merger involving its previous auditor, Moss Adams LLP. The audit reports from Moss Adams for the fiscal years ending December 31, 2024, and 2023 did not contain any adverse opinions. These developments highlight Vivos’ ongoing efforts to expand its reach and enhance its offerings in the sleep disorder treatment market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.